A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

NCT05040906 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

416

Enrollment

INDUSTRY

Sponsor class

Conditions

Recruiting

Interventions

DRUG: H02+CHOP
DRUG: Rituxan +CHOP

Sponsor

Shandong New Time Pharmaceutical Co., LTD